Over the projection period, prominent market players are anticipated to utilise more organic techniques, such as funding, to increase their market share. For instance, the biotechnology business Agenus Inc. reported in July 2020 that Betta Pharmaceuticals Co., Ltd. had closed a US$ 20 million equity investment at US$ 4.03 per share, bringing the total received to US$ 35 million. With the help of this investment, Betta will be granted exclusive rights for the research and development of balstilimab and zalifrelimab as monotherapies and in combination, excluding intravenous delivery, throughout greater China. The global market for immuno-oncology medications is anticipated to grow as inorganic tactics such product approval by regulatory bodies like the European Commission (EC) are being adopted. Over the forecast period, the global market for immuno-oncology medications is anticipated to be driven by ongoing research and development by prominent industry players. Due to increased research and development by major market players in that region, North America is anticipated to hold the biggest market share in the global market for immuno-oncology medications during the course of the forecast year.
As per Coherent Market Insights, during the projection period (2022-2030), the market for Immuno-Oncology medications is anticipated to grow at a CAGR of 16.8%, reaching an estimated value of US$ 17,394.2 million in 2022.
Prominent Companies in the Immuno-oncology Drugs Industry:
Novartis AG,
The company was founded in March 1996 and has its main offices in Basel, Switzerland, and Cambridge, Massachusetts, in the United States. Novartis provides coverage for all types of medications, including authorization, over-the-counter, immunisations, diagnostics, eyewear, and veterinary care. Through its firms, Novartis engages in a number of direct activities, including managing, advertising, operations, and research.
Pfizer Inc.,
The company was established in 1849, and Manhattan, New York City, is where its corporate headquarters are situated. Through the creation of pharmaceuticals and vaccines, Pfizer seeks to enhance the fields of immunology, cancer, the heart, endocrinology, and neurology. In October 2022, the business successfully acquired Biohaven Pharma's calcitonin gene-related peptide programmes. Pfizer purchased Amplyx Pharmaceuticals in April 2021, which included the rights to the antifungal drug fosmanogepix (APX001).